7210 Wareham Drive, Tampa, FL 33647
Jan. 6, 2026 Novo Nordisk launched the pill version of its popular obesity medication Wegovy on Monday Jan. 5. The firm aimed to capture patients with a cash-pay discount — $149 a month for the lowest starting doses of the medication through April 15. It’s also trying to onboard new patients through a growing number […]
Telehealth Companies Offer Novo’s Wegovy pill Read More »
Dec. 22, 2025 The U.S. Food and Drug Administration on Dec. 22 approved a pill version of Novo Nordisk’s weight-loss drug Wegovy, the first daily oral medication for obesity treatment. The once-daily tablet — called the Wegovy pill — is the “first and only” oral GLP-1 medicine, or glucagon-like peptide-1, receptor agonists, according to Novo
FDA Approves Novo’s Wegovy Weight Loss Pill Read More »
Nov. 17, 2025 Due to increased competition in the weight loss market and intense pressure from President Trump, Novo Nordisk announced Monday that it is lowering prices for its blockbuster obesity and diabetes drugs for cash-paying patients. This is is the latest step in the firm’s efforts to provide discounts to Americans willing to buy
Novo Nordisk Lowers Weight Loss Drug Prices Read More »
Nov. 6, 2025 CNBC reported today that President Donald Trump announced deals with Eli Lilly and Novo Nordisk and Eli Lilly toslash the prices of some of their obesity drugs, including upcoming pills, in a landmark effort to expand access to the costly blockbuster treatment. The agreements will cut prices of so-called GLP-1 drugs for
Trump Cuts Deal To Lower Weight Loss Drug Prices Read More »
Nov. 6, 2025 Weight loss products are a major part of Herbalife’s business, accounting for 55% of total sales for the first nine months of 2025. According to Stephan Gratziani, CEO,… “Herbalife’s third-quarter performance reflects continued progress in our transformation strategy, as well as disciplined financial and operational execution. With North America returning to growth
Herbalife Reports 3rd Qtr. Results Read More »
Nov. 6, 2025 According to WW management: “WeightWatchers is entering a new era, uniquely positioned at the intersection of medical innovation and behavioral science, to lead this rapidly evolving weight health market,” said Tara Comonte, CEO of WeightWatchers. “GLP-1s are a breakthrough in obesity care, but real success, with or without medication, comes from combining
Weight Watchers Reports 3rd Qtr. Results Read More »
Nov. 4, 2025 Management reported the foillowing: Revenue: $89.4 million, with revenue per active earning coach of $4,585 Active Coaches: Independent active earning OPTA VIA ® coaches of 19,500 Net Loss: $2.3 million or $0.21 loss per diluted share Strong Balance Sheet: $173.5 million in cash, cash equivalents, and investment securities with no debt “We’re transforming Medifast from a
Medifast Reports Q3 Results – Slide Continues Read More »
Oct. 31, 2025 Zach Yadegari is the 18-year old co-founder and CEO of Cal AI, a calorie-tracking mobile app he launched from his parents’ home in Roslyn, New York, in May 2024. It has amassed 8.3 million downloads so far and growing. The company says that it nets $1.4 million per month profit, after expenses,
Sucess Story – Cal AI Weight Loss App Read More »
Oct. 15, 2025 A new Consumer Reports investigation has found that most protein powders and shakes — dietary supplements that have exploded in popularity in recent years — contain more lead in a single serving than is considered safe to ingest in an entire day. Technically, there’s no amount of lead that is considered safe
Study Finds high levels of lead in protein powders, shakes Read More »
Sept. 23, 2025 Soon, there may be a promising alternative for the needle-averse, as results of a recent Phase 3 trial confirmed that a daily 25-milligram semaglutide pill can trigger significant weight loss. “We all knew this was coming, and we all feel that it could potentially be a game changer in terms of adopting
Weight Loss Pills Are On The Horizon Read More »